Search

Yesterday, PTC Therapeutics announced the first results of the CardinALS study. Unfortunately, the analyses showed that on both the primary and secondary endpoints, the drug Utreloxastat shows no improving or slowing effect in people with ALS. The study has therefore been discontinued with immediate effect.

INARC is hosting a networking event during the International Symposium on MND/ALS.